Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.

Publication ,  Journal Article
Berger, JS; Becker, RC
Published in: Platelets
August 2009

Platelet-initiated acute thrombosis and coronary embolization are fundamental to the pathophysiology of acute coronary syndromes. Pharmacotherapies aimed at disrupting platelet function via the P2Y(12) receptor have been successful at reducing the incidence of vascular events in randomized clinical trials. However, with the emergence of third and fourth generation drugs, several important considerations remain, including metabolism, timing of onset, variability in platelet response or "resistance", monitoring ability, and off-target effects. These fundamental properties and distinct profiles may shape the future of cardiovascular therapeutics. Investigation of practical ex vivo platelet performance measurement tools is actively proceeding and may provide important information for patient management.

Duke Scholars

Published In

Platelets

DOI

EISSN

1369-1635

ISSN

0953-7104

Publication Date

August 2009

Volume

20

Issue

5

Start / End Page

302 / 315

Related Subject Headings

  • Treatment Outcome
  • Thrombosis
  • Receptors, Purinergic P2Y12
  • Receptors, Purinergic P2
  • Platelet Function Tests
  • Humans
  • Embolism
  • Coronary Artery Disease
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Berger, J. S., & Becker, R. C. (2009). A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes. Platelets, 20(5), 302–315. https://doi.org/10.1080/09537100903038512
Berger, Jeffrey S., and Richard C. Becker. “A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Platelets 20, no. 5 (August 2009): 302–15. https://doi.org/10.1080/09537100903038512.
Berger, Jeffrey S., and Richard C. Becker. “A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Platelets, vol. 20, no. 5, Aug. 2009, pp. 302–15. Epmc, doi:10.1080/09537100903038512.

Published In

Platelets

DOI

EISSN

1369-1635

ISSN

0953-7104

Publication Date

August 2009

Volume

20

Issue

5

Start / End Page

302 / 315

Related Subject Headings

  • Treatment Outcome
  • Thrombosis
  • Receptors, Purinergic P2Y12
  • Receptors, Purinergic P2
  • Platelet Function Tests
  • Humans
  • Embolism
  • Coronary Artery Disease
  • Cardiovascular System & Hematology
  • 3201 Cardiovascular medicine and haematology